BPMC vs. APLS, IONS, BBIO, OGN, CYTK, ELAN, PRGO, NUVL, ALPN, and ITCI
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Apellis Pharmaceuticals (APLS), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), Organon & Co. (OGN), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Perrigo (PRGO), Nuvalent (NUVL), Alpine Immune Sciences (ALPN), and Intra-Cellular Therapies (ITCI). These companies are all part of the "pharmaceutical preparations" industry.
Blueprint Medicines (NASDAQ:BPMC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, community ranking, profitability, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, Blueprint Medicines had 31 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 56 mentions for Blueprint Medicines and 25 mentions for Apellis Pharmaceuticals. Blueprint Medicines' average media sentiment score of 0.55 beat Apellis Pharmaceuticals' score of 0.24 indicating that Blueprint Medicines is being referred to more favorably in the media.
Blueprint Medicines has a net margin of -102.15% compared to Apellis Pharmaceuticals' net margin of -133.34%. Apellis Pharmaceuticals' return on equity of -178.60% beat Blueprint Medicines' return on equity.
Blueprint Medicines presently has a consensus target price of $100.31, indicating a potential downside of 7.78%. Apellis Pharmaceuticals has a consensus target price of $76.67, indicating a potential upside of 81.25%. Given Apellis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Apellis Pharmaceuticals is more favorable than Blueprint Medicines.
96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 3.9% of Blueprint Medicines shares are held by company insiders. Comparatively, 7.5% of Apellis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Blueprint Medicines has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Blueprint Medicines has higher earnings, but lower revenue than Apellis Pharmaceuticals. Blueprint Medicines is trading at a lower price-to-earnings ratio than Apellis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines received 201 more outperform votes than Apellis Pharmaceuticals when rated by MarketBeat users. Likewise, 67.80% of users gave Blueprint Medicines an outperform vote while only 67.45% of users gave Apellis Pharmaceuticals an outperform vote.
Summary
Apellis Pharmaceuticals beats Blueprint Medicines on 10 of the 18 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
